Julie Bines (MBBS, MD, FRACP, AGAF), is a clinician and researcher working in Melbourne, Australia. Alongside being a professor and deputy head of the Department of Paediatrics at the University of Melbourne,[1] she is also a paediatric gastroenterologist at the Royal Children's Hospital Melbourne[2] and is the leader of the Enteric Diseases group at the Murdoch Children's Research Institute.[3] Bines is the joint head of the WHO Collaborative Centre for Child Health[4] and founding member of Women in Global Health Australia.[5]

Career and research

Bines attended Monash University, graduating with a Bachelor of Medicine, Bachelor of Surgery (MBBS) in 1982, later attaining her Doctorate of Medicine from the University of Melbourne in 1990.[6] She trained as a clinical and research fellow in Paediatric Gastroenterology and Nutrition at Massachusetts General hospital and Harvard Medical School, Boston (1988–91) and a postdoctoral fellow at the Massachusetts Institute of Technology (1989–91).[6] After travelling through Asia, Africa and Europe for 12 months during her residency at the Royal Children's Hospital, Bines became fixed on pediatrics with a focus on addressing the global disparity in healthcare.[1] Beyond her contributions to rotavirus research and vaccine development, Bines' recent research has expanded to investigate the impact of the COVID pandemic on women and children worldwide.[7]

Novel rotavirus vaccine development

Bines and her team developed a novel oral rotavirus vaccine (RV3-BB) as a global vaccine against infant rotavirus infection based on a naturally occurring and attenuated human strain of rotavirus originally isolated from healthy babies.[8] Clinical trials were carried out in Australia, New Zealand, Malawi and Indonesia, achieving 95% protection about severe rotavirus-associated gastroenteritis in the first year of life and up 75% protection in infants up to 18 months of age.[9] Most notably, this vaccine has been developed to improve efficacy and availability in developing countries by optimizing the delivery time and developing manufacturing processes to reduce production costs.[10]

Outreach

Bines has been involved in outreach campaigns to dispel myths and misinformation about vaccines,[11] as well as appearing on national radio to talk about her work.[12]

Awards and honours

  • 2021 Fellow of the Australian Academy of Health and Medical Sciences
  • 2021 Eureka Prize, Research and Innovation Category[13]
  • 2007 American Gasteoenterology Association Fellow[14]
  • 2004 NHMRC Practitioner Fellowship[15]

Selected publications

  • Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial[8]
  • Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial[9]
  • Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine[10]
  • Genotype Diversity before and after the Introduction of a Rotavirus Vaccine into the National Immunisation Program in Fiji[16]
  • Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia[17]
  • Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19[18]
  • Conquering rotavirus: From discovery to global vaccine implementation[19]

References

  1. 1 2 Cigognini B (2 December 2021). "Professor Julie Bines". Melbourne Medical School. Retrieved 7 April 2022.
  2. ↑ "Gastroenterology and Clinical Nutrition : The team". www.rch.org.au. Retrieved 7 April 2022.
  3. ↑ "Enteric Diseases - Murdoch Children's Research Institute". www.mcri.edu.au. Retrieved 7 April 2022.
  4. ↑ "WHOCC - WHO Collaborating Centres". apps.who.int. Retrieved 7 April 2022.
  5. ↑ "Steering Committee". Women in Global Health Australia. Retrieved 7 April 2022.
  6. 1 2 "Professor Julie Bines | Murdoch Children's Research Institute". www.mcri.edu.au. Retrieved 7 April 2022.
  7. ↑ "GLHAM National COVID Briefing - The knock-on effect: how the pandemic is uniquely impacting the health of women and girls". Australian Global Health Alliance. Retrieved 7 April 2022.
  8. 1 2 At Thobari J, Damayanti W, Haposan JH, Nirwati H, Iskandar K, Fahmi J, et al. (July 2021). "Safety and immunogenicity of human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, and neonates in Indonesia: Phase I Trial". Vaccine. 39 (33): 4651–4658. doi:10.1016/j.vaccine.2021.06.071. PMID 34244006. S2CID 235787849.
  9. 1 2 Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, et al. (December 2015). "Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial". The Lancet. Infectious Diseases. 15 (12): 1389–1397. doi:10.1016/S1473-3099(15)00227-3. PMID 26318715.
  10. 1 2 Hamidi A, Hoeksema F, Velthof P, Lemckert A, Gillissen G, Luitjens A, et al. (April 2021). "Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine". Vaccine. 39 (15): 2048–2059. doi:10.1016/j.vaccine.2021.03.033. PMC 8062787. PMID 33744044.
  11. ↑ Choahan N (2 October 2018). "The science of immunisation: Dispelling vaccination myths". Retrieved 7 April 2022.
  12. ↑ "Rotavirus scientist among Eureka Prize finalists". ABC Radio National. 2 September 2021. Retrieved 7 April 2022.
  13. ↑ Vince C (2 September 2021). "Scientists pave the way for a brighter future in Research & Innovation category at 2021 Australian Museum Eureka Prizes". The Australian Museum. Retrieved 7 April 2022.
  14. ↑ "Current AGA Fellows". American Gastroenterological Association. Retrieved 7 April 2022.
  15. ↑ "Game changer through a new vaccine for Rotavirus | NHMRC". www.nhmrc.gov.au. Retrieved 7 April 2022.
  16. ↑ Thomas S, Donato CM, Covea S, Ratu FT, Jenney AW, Reyburn R, et al. (March 2021). "Genotype Diversity before and after the Introduction of a Rotavirus Vaccine into the National Immunisation Program in Fiji". Pathogens. 10 (3): 358. doi:10.3390/pathogens10030358. PMC 8002601. PMID 33802966.
  17. ↑ Danchin MH, Bines JE, Watts E, Cowley D, Pavlic D, Lee KJ, et al. (April 2020). "Rotavirus specific maternal antibodies and immune response to RV3-BB rotavirus vaccine in central java and yogyakarta, Indonesia". Vaccine. 38 (16): 3235–3242. doi:10.1016/j.vaccine.2020.02.087. PMID 32160948. S2CID 212677834.
  18. ↑ Tosif S, Neeland MR, Sutton P, Licciardi PV, Sarkar S, Selva KJ, et al. (November 2020). "Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19". Nature Communications. 11 (1): 5703. Bibcode:2020NatCo..11.5703T. doi:10.1038/s41467-020-19545-8. PMC 7658256. PMID 33177504.
  19. ↑ Bines JE, Kirkwood CD (January 2015). "Conquering rotavirus: from discovery to global vaccine implementation". Journal of Paediatrics and Child Health. 51 (1): 34–39. doi:10.1111/jpc.12815. PMID 25586843. S2CID 5492363.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.